Host Response Core People
Director, Host Response Core
Dr. Frevert, Director of this core, is a veterinary pathologist and basic scientist. His research focuses on the role of proteoglycans in controlling the innate immune response to infection with an emphasis on understanding the mechanisms whereby glycosaminoglycans control chemokine function and neutrophil migration in the lungs. Dr. Frevert has considerable experience with all the histology and imaging technologies that the Immunology Core provides and with the development of animal models of inflammation and infection. He was the Director of the Molecular Imaging Core at the VA Puget Sound Medical Center for over 10 years, and he is currently the Director of the Histology and Imaging Core and Co-Director of the Comparative Pathology Program.
Dr. Liggitt is a Professor and Chairman of the Department of Comparative Medicine, School of Medicine, University of Washington (UW). Dr. Liggitt is a board-certified comparative pathologist who also serves as an advisor to the UW ITHS Preclinical Research Development Network (PRDN) as well as the Cystic Fibrosis Foundation and others. Dr. Liggitt is an authority in the development and evaluation of models of human diseases and has published more than 150 scientific papers in this and related areas. He has particular expertise in the use of these models and associated systems for the preclinical development, safety/toxicity evaluation, and approval of biologic-based drugs. He was formerly an Associate Director of Pharmacology at Genentech Inc. and when there established the preclinical pathology section. Dr. Liggitt will provide a key link between the preclinical consultation in the Clinical Core group and the Comparative Pathology group in the Host Response Core. Dr. Liggitt will consult with investigators who require advise for preclinical studies. He will also assist with toxicology studies performed in animal models.
Dr. Skerrett is a Professor in the Division of Pulmonary and Critical Care Medicine. Dr. Skerrett’s research focuses on gaining a better understanding of the cellular and molecular basis of pulmonary host defenses against infection. Dr. Skerrett provides additional expertise in the host response to Pseudomonas aeruginosa and other bacterial pathogens frequently encountered in CF patients. His clinical knowledge will be important when interpreting data collected from animal models and patients with CF. Shawn will also play a key role in the interactions between the HRC and Clinical Core.